Emmes, a global, full-service Clinical Research Organization (CRO), has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany.  Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-up studies.  It has conducted more than 400 studies across a range of therapeutic areas. 
 
This is the third acquisition for Emmes in the last year, having previously purchased Neox, headquartered in the Czech Republic, in December 2020 and UK-based Orphan Reach in May 2021.  The acquisition of Institut Dr. Schauerte augments Emmes’ global reach by expanding the company’s presence in Germany and adding new long-term strategic relationships with global biopharma companies.  With Institut Dr. Schauerte, Emmes now has more than 1,200 employees.
 
Emmes Chief Executive Officer Dr. Christine Dingivan said, “This is another positive step in our growth and diversification strategy.  Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research. Its agile, technology-enabled approach is a perfect fit with Emmes and will enhance our digital capabilities.”
 
Institut Dr. Schauerte also expands Emmes’ technology product line with its ClinDoc tool, a secure, intuitive CFR21 Part 11 compliant Electronic Data Capture (EDC) solution.  It includes multi-language capabilities and interfaces for clinical trial management systems, electronic health records, and mobile health data from apps and wearables. 
 
Institut Dr. Schauerte CEO and Founder Dr. Wulfram Schauerte said, “Our deep expertise in RWE and a thriving set of offices in Munich and Cottbus, Germany, will be strong assets in Emmes’ global growth plans.  We are excited about joining the company and working with our new colleagues in Emmes Europe.  We share much in common; in addition to our dedication to high research standards, we place great value on employee engagement and long-term client relationships.” 
 
Dr. Schauerte and Institut Dr. Schauerte’s leaders and staff will continue in their current roles.